Novartis Ag Stock News

This may be the year when the world comes to terms with the persistent reality of Covid-19 and reaches a new sense of normalcy, Novartis CEO Vas Narasimhan said

Splash Beverage (SBEV) -18%.Silvergate Capital SI -13% on Q4 results.Molecular Partners MOLN -14% Novartis and Molecular Partners finalize licensing agreement for

Molecular Partners (MOLN) ADRs have lost ~16.1% in the pre-market after announcing a licensing agreement with Novartis (NVS) for Ensovibep, its DARPin antiviral candidate for COVID-19

Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

Each of these companies possesses solid fundamentals and trades at reasonable valuations.

Novartis (NVS) ADRs are trading flat in the pre-market after Morgan Stanley lowered its rating on the Swiss Pharma giant to Equal Weight from Overweight, noting a lack of catalysts

These seven long-term stocks are among the best picks for truly long-term investors looking for companies to hold for the next decade. The post 7 Best Long-Term Stocks to Buy and Hold for the Next Dec

Following is the unofficial transcript of a CNBC exclusive interview with Novartis (NYSE:NVS) CEO Dr. Vas Narasimhan on CNBCs Squawk on the Street (M-F 9AM 11AM ET) today, Wednesday, January 12th. Following is a link to video on CNBC.com: Q4 2021 hedge fund letters, conferences and more Novartis CEO: Were Moving Toward Filing Covid []

Novartis CEO Vas Narasimhan sits down with CNBC's Meg Tirrell and the 'Squawk on the Street' team to discuss the company's latest Covid-19 treatment, which it licensed from Molecular Partners.

DUBLIN , Jan. 12, 2022 /PRNewswire/ -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2021" report has been added to ResearchAndMarkets.com''s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2021 report provides comprehensive access to available deals and contract documents for over 2,900 clinical stage deals. The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner''s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.

Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.

(RTTNews) - Molecular Partners AG (MOLN) and Novartis announced positive data from phase 2 study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19. A total of 407 patients were recruited in the Phase 2 study and ensovibep was safe and well-tolerated at all doses (75mg, 225mg and 600mg) - with 75mg the planned dose for further

Molecular Partners (MOLN) and Novartis (NVS) announce that Part A of the EMPATHY clinical trial, that compared single intravenous doses of ensovibep vs